Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes

American Journal of Hypertension

Volumn 10, Issue 4 I, 1997, Pages 440-446

  Morikang, Ebenezer ^a   Benson, Stephen C ^a   Kurtz, Theodore W ^b   Pershadsingh, Harrihar A ^c,d  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Bethesda Pharmaceuticals Inc   (United States)

^d K M Medical Center   (United States)

Author keywords

coronary artery; differentiation; DNA synthesis; growth factor; human; platelet derived growth factor; proliferation; thiazolidinedione; vascular smooth muscle

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ACTIN; CIGLITAZONE; PLATELET DERIVED GROWTH FACTOR; TROGLITAZONE;

AORTA; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CORONARY ARTERY; CULTURE MEDIUM; CYTOTOXICITY; DNA SYNTHESIS; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; SERUM;

AORTA; CELL DIVISION; CELLS, CULTURED; CHROMANS; CORONARY VESSELS; HUMANS; HYPOGLYCEMIC AGENTS; MUSCLE, SMOOTH, VASCULAR; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031003829     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00406-2     Document Type: Article

References (36)

1. Bressler R, Johnson D: New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992; 15:792-805.
2. Hofmann CA, Colca JK: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992;15:1075-1078.
3. Pershadsingh HA, Szollosi J, Benson S, et al: Effects of ciglitazone or blood prersure and intracellular calcium metabolism. Hypertension 1993;21:1020-1023.
4. Kotchen TA: Attenuation of experimental hypertension with agents that increase insulin sensitivity. Drug Dev Res 1994;100-103.
5. Dubey RK, Zhang HY, Reddy SR, et al: Piogiitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993; 265:R726-R732.
6. Yoshioka S, Nishino H, Shiraki T. et al: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993;42:75-80.
7. Kemnitz JW, Elson DF, Roecker EB, et al: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes 1994; 43:204-211.
8. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 1995;96:354-360.
9. Nolan JJ, Ludvik B, Beerdsen P, et al: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engi J Med 1994; 331:1188-1193.
10. Ogihara T, Rakugi H, Ikegami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-320.
11. Zhang F Sowers JR, Ram JL, et al: Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 1994;24:170-175,
12. Pershadsingh HA, Szollosi J, Benson SC, Kurtz TW: Pharmacological reversal of hyperinsulinemia is associated with a reduction in blood pressure: a novel approach to the treatment of hypertension (abst). Hypertension 1992;20:321.
13. Law RE, Xi XP, Hsueh WA: Troglitazone inhibits insulin, EGF, and PDGF mitogenic signal transduction in A10 vascular smooth muscle (VSM) and mesangial cel (abst). Hypertension 1995;26:553.
14. Sandouk T, Reda D, Hofmann C: Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442a cells. Am J Physiol 1993;264:C1600-C1608.
15. Kletzien RF, Clarke SD, Ulrich RG: Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Molec Pharmacol 1992;41:393-398.
16. Benson S, Belton J, Scheve L: Regulation of lung fibroblast proliferation and protein synthesis by bronchiolar lavage in experimental silicosis Environ Res 1986; 41:61-78.
17. Korzeniewski C, Callewaert D: An enzyme-release assay for natural cytotoxicity. J Immunol Meth 1983; 64:313-320.
18. Wilson AP: Cytotoxicity and viability assays, in Freshney RI (ed): Animal Cell Cultures. A Practical Approach. IRL Press, New York, 1992, pp 263-303.
19. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
20. Wilcox J, Smith K, Williams, LT, et al: Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 1988;82:1134-1143.
21. Ross R, Raines EW, Bowen-Pope DF: The biology of platelet-derived growth factor. Cell 1986;46:155-169.
22. Jawien A, Bowen-Pope DF, Linder V, et al: Plateletderived growth factor promotes smooth muscle migration and intimai thickening in a rat model of balloon angioplasty. J Clin Invest 1992;89:507-511.
23. Berk FC, Alexander RW, Brock TA, et al: Vasoconstriction: a new activity for platelet-derived growth factor Science 1986;232:87-90.
24. Ross R, Masuda J, Raines EW, et al: Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990;248:1009-1012.
25. Ferns GAA, Raines EW, Sprugel KH, et al: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-1132.
26. Chamley-Campbell JH, Campbell GR, Ross R: Phenotypic-dependent response cf cultured aortic smooth muscle to serum mitogens. J Cell Biol 1981;89;379-391.
27. Thyberg J, Hedin U, Sjolund M: Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 1990;10:966-990.
28. Gabbiani G, Kocher O, Bloom WS: Actin expression in smooth muscle cells of rat aortic intimai thickening, human atheromatous plaque, and cultured rat aortic media. J Clin Invest 1984;73:148-157.
29. Indolfi CI, Esposito G, Di Lorenzo E, et al: Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation 1995;92:1230-1235.
30. MacLeod DC, Strauss BH, de John M: Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol 1994;23:69-75.
31. Lehmann JM, Moore LB, Smith-Oliver TA: An antidiabetic thiazolidinedione is a high affinity ligand for per oxisome proliferator-activated receptorγ (PPARγ). J Biol Chem 1995;12953-12956.
32. Wahli W, Braissant O, Desvergne B: Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chemistry & Biology 1995;2:261-266.
33. Desvergne B, Wahli W: PPAR: a key nuclear factor in nutrient / gene interactions? Inducible Gene Expression 1995;1:142-175.
34. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPARγ, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
35. Law RE, Meehan WP, Xi X-P, et al: Troglitazone inhibits vascular smooth muscle muscle cell growth and intimal hyperplasia (abst). Diabetes 1996;45(suppl 2):66A.
36. Igarashi M, Takeda Y, Mori S, et al: Pioglitazone reduces the amount of smooth muscle cells of arterial intimai thickening lesion induced by balloon catherterization (abst). Diabetes 1996;45(Duppl 2):129A